## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.35 indicates fundamental undervaluation. Quality metrics strong (ROE 18%). Caution: declining volume (54% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($304.93)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. UnitedHealth Unwinds Last South America Asset In $1 Billion Banmedica Sale**
- Source: Benzinga | 20251201T084600 | Neutral | Relevance: 100%
- UnitedHealth Group (NYSE: UNH) has agreed to sell its remaining South American operation, Banmedica, to Brazilian private equity firm Patria Investments for $1 billion. This move is part of UnitedHealth's strategy to streamline operations and support turnaround efforts under CEO Stephen Hemsley, following previous exits from Brazil and Peru. Banmedica operates in Chile and Colombia, covering 1.7 million health insurance members.

**2. UnitedHealth Group (UNH) Valuation: Is Recent Weakness an Opportunity?**
- Source: Simply Wall Street | 20251129T212124 | Somewhat-Bullish | Relevance: 99%
- UnitedHealth Group's stock (UNH) has experienced significant volatility, with recent weakness sparking investor interest in its valuation. Despite short-term recovery, the stock remains down year-to-date and over the past year, trading below analyst price targets. The article explores whether this weakness presents an undervalued entry point, highlighting a narrative of undervaluation at $386.72 driven by expectations of margin rebound and operational improvements within Optum.

**3. UnitedHealth to exit Latin America with $1B Banmedica sale - Reuters (UNH:NYSE)**
- Source: Seeking Alpha | 20251201T043700 | Neutral | Relevance: 99%
- UnitedHealth Group (UNH) has reportedly agreed to sell its remaining South American unit, Banmedica, to Brazilian private equity firm Patria Investments (PAX) for approximately $1 billion. This sale signifies UnitedHealth's exit from the Latin American market. The deal, cited by Reuters based on familiar sources, has already been signed.

**4. UnitedHealth agrees to sell South American business to private equity firm Patria for $1 billion, sources say**
- Source: Reuters | 20251130T182100 | Somewhat-Bullish | Relevance: 98%
- UnitedHealth Group has agreed to sell its Banmedica South American business to Brazilian private equity group Patria Investments for $1 billion. This sale marks UnitedHealth's complete exit from Latin America, reducing distractions and supporting the company's turnaround efforts led by CEO Stephen Hemsley. The agreement was signed on Saturday and an announcement is expected on Monday.

**5. UnitedHealth Signs Deal to Sell Banmedica Business to Private Equity Firm for $1 Billion**
- Source: MarketScreener | 20251201T103400 | Somewhat-Bullish | Relevance: 98%
- UnitedHealth has reached an agreement to sell its South American business, Banmedica, to private equity firm Patria for $1 billion. This move comes as UnitedHealth adjusts its global operations. The deal is expected to be officially announced soon.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 11.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.35 suggests fair value with growth premium. Forward P/E 18.3x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $297.5B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.35 |
| Forward P/E | 18.3 |
| Current P/E | 19.8 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 5.3pp (needs >4.0% for momentum thesis). Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (1.36), confirming momentum. RSI neutral at 44. Volume at 54% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.33% (CS: 34) | Neutral |
| RSI_14 | 44.4 | Neutral |
| MACD Histogram | 1.36 | Bullish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 0.942x | Below |
| vs SMA200 | 0.884x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $323.21
- **Stop Loss:** $304.93 (5.7% risk)
- **Target:** $359.77 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 41
- **Position Value:** $13,251.61
- **Portfolio %:** 13.25%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*